However, a crucial aspect of thisprocess that has remained unexplored is the possibility that HER2 gene-amplifiedbreast carcinoma cells might also exploit the cytoprotective role of autophagy to escape fromHER2-targeted therapies ab initio. This evidence concerns the gene ERBB2 and carcinoma.